565 Cutaneous delivery of LEKTI via an engineered strain of staphylococcus epidermidis for the treatment of netherton syndrome
Mootien S, Leger R, Martins D, Whitfill T. 565 Cutaneous delivery of LEKTI via an engineered strain of staphylococcus epidermidis for the treatment of netherton syndrome. Journal Of Investigative Dermatology 2024, 144: s99. DOI: 10.1016/j.jid.2024.06.581.Peer-Reviewed Original ResearchStrains of Staphylococcus epidermidisEngineered strainStaphylococcus epidermidisCutaneous deliveryNetherton syndromeEpidermidisSyndromeLEKTIPreclinical development of ATR04-484, an auxotrophic strain of Staphylococcus epidermidis, for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity.
Whitfill T, Mootien S, Leger R. Preclinical development of ATR04-484, an auxotrophic strain of Staphylococcus epidermidis, for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity. Journal Of Clinical Oncology 2024, 42: e24074-e24074. DOI: 10.1200/jco.2024.42.16_suppl.e24074.Peer-Reviewed Original ResearchEpidermal growth factor receptorMethicillin resistanceReconstructed human epidermisProphylactic settingS. aureusMRSA growthDermal toxicityColony-forming unitsPatients treated with EGFR inhibitorsTreatment of advanced lungTreatment of epidermal growth factor receptorSignaling pathwayStrains of Staphylococcus epidermidisEpidermal growth factor receptor pathwayQuality of lifeSuppress host defensesLevels of Staphylococcus aureusPig skinHuman cornea-like epitheliumS. aureus growthIrritation potentialCornea-like epitheliumAdherence to therapyInhibit S. aureusEGFR-mediated signaling pathways